3D-QSAR CoMFA study on human glutaminyl cyclase inhibitors

Internet Electronic Journal of Molecular Design

Volumn 6, Issue 10, 2007, Pages 320-330

  Nayana, Munuganti Ravi Shashi ^a   Sekhar, Yadavalli Nataraja ^a   Kumari, Nunna Siva ^a   Mahmood, Shaik ^a  

^a OSMANIA UNIVERSITY   (India)

Author keywords

3D QSAR; CoMFA; Comparative molecular field analysis; Human glutaminyl cyclase; Imidazole derivatives; Quantitative structure activity relationships

Indexed keywords

EID: 38149080582     PISSN: None     EISSN: 15386414     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. K. Richter, E. Kawashima, R. Egger, and G. Kreil, Biosynthesis of thyrotropin releasing hormone in the skin of Xenopus laevis: partial sequence of the precursor deduced from cloned cDNA. EMBO. J. 1984, 3, 617-621.
2. A. Oberg, J.M. Ruysschaert, M. Azarkan, N. Smolders, S. Zerhouni, R. Wintjens, A. Amrani, and Y. Looze, Papaya glutamine cyclase, a plant enzyme highly resistant to proteolysis, adopts an all-beta conformation. Eur. J. Biochem. 1998, 258, 214-222.
3. P. A. Sykes, S. J. Watson, J. S. Temple, and R. C. Jr. Bateman, Evidence for tissue-specific forms of glutaminyl cyclase, FEBS Lett.1999, 455, 159-161.
4. A. C. Awade, P. Cleuziat, T. Gonzales, and J. Robert-Baudouy, Pyrrolidone carboxyl peptidase (Pcp): An enzyme that removes pyroglutamic acid (pGlu) from pGlu-peptides and pGlu-proteins. Proteins. 1994, 20, 34-51.
5. J. S. Garavelli, The RESID database of protein structure modifications: 200 update, Nucleic Acids Res. 2000, 563, 191-196.
6. C. Morgan, M. Colombres, M. T. Nunez, and N. C. Inestrosa, Structure and function of amyloid in Alzheimer's disease. Prog. Neurobiol. 2004, 74, 323-349.
7. T. Hashimoto, T. Wakabayashi, A. Watanabe, H. Kowa, R. Hosoda, A. Nakamura, I. Kanazawa, T. Arai, K. Takio, and D. M. A. Mann. CLAC: a novel Alzheimer amyloid plaque component derived from a transmembrane precursor, CLAC-P/collagen type XXV. EMBO J. 2002, 21, 1524-1534.
8. T. C. Saido, T. Iwatsubo, D. M. Mann, H. Shimada, Y. Ihara, and S. Kawashima, Involvement of pyroglutamine endolysis followed by pyroglutamate formation in the pathogenesis of triplet repeat/pyroglutamine-expansion deseases. Neuron 1995, 14, 1524-1534.
9. Y. M. Kuo, M. R. Emmerling, A. S. Woods, R. J. Cotter, and A. E. Roher, Biochem. Biophys. Res. Commun. 1997, 237, 188-191.
10. C. Russo, E. Violani, S. Salis, V. Venezia, V. Dolcini, G. Damonte, U. Benatti, C. D'Arrigo, and P. Carlo, J. Neurochem. 2002, 82, 1480-1489.
11. Y. Harigaya, T. C. Saido, C. B. Eckman, C. M. Prada, M. Shoji, and S. G. Younkin, Isolation, Chemical Characterization, and Quantitation of Aβ 3-Pyroglutamyl Peptide from Neuritic Plaques and Vascular Amyloid Deposits. Biochem. Biophys. Res. Commun. 2000, 276, 422-427.
12. M. Buchholz, U. Heiser, S. Schilling, A. J. Neistroj, K. Zunkel, and H. U. Demuth, The first potent inhibitors for Human Glutaminyl Cyclase: Synthesis ans structure-Activity relationship. J. Med. Chem. 2006, 49, 664-677.
13. S. M. Vadlamudi and V. M. Kulkarni, 3D-QSAR of Protein Tyrosine Phosphatase 1B Inhibitors by Genetic Function Approximation. Internet Electron. J. Mol. Des. 2004, 3, 586-609.
14. O. Ivanciuc, 3D QSAR Models. In: QSPR/QSAR Studies by Molecular Descriptors. Ed.: M. V. Diudea. Nova Science, Huntington, N.Y., 2001, pp. 233-280.
15. http://www.coepra.org
16. R. D. Cramer III, D. E. Patterson, and J. D. Bunce, Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins. J. Am. Chem. Soc. 1988, 110, 5959-5967.
17. G. R. Desiraju, B. Gopalakrishnan, R. K. Jetti, A. Nagaraju, J. D. Raveendra, A. Sharma, and R. Thilagavathi, Computer-Aided Design of Selective COX-2 Inhibitors: Comparative Molecular Field Analysis, Comparative Molecular Similarity Indices Analysis, and Docking Studies of Some 1,2-Diarylimidazole Derivatives. J. Med. Chem. 2002, 45, 4847-4857.
18. S. K. Singh, N. Dessalew, and P. V. Bharatam, 3D-QSAR CoMFA study on indenopyrazole derivatives as cyclin dependent kinase 4 (CDK4) and cyclin dependent kinase 2 (CDK2) inhibitors. Eur. J. Med. Chem. 2006, 41, 1310-1319
19. R. Thilagavathi and A. K. Chakraborti, Importance of Alignment in Developing 3-D QSAR Models of 1,5-Diaryl Pyrazoles for the Prediction of COX-2 Inhibitory Activity. Internet Electron. J. Mol. Des. 2005, 4, 603-612.
20. SYBYL, version 6.7; Tripos Associates: St. Louis, MO, 2000
21. M. Clark, R. D. Cramer III, and N. Van Opdenbosch, Validation of the general purpose Tripos 5.2 force field, J. Comput. Chem, 1989, 10, 982-1012.